Articles On Medical Developments International (ASX:MVP)

The S&P/ASX 200 Index (ASX: XJO) has risen by 4.67% since last Friday’s close (6 November) to 6,466 points. Global investors have snapped up pandemic-hit shares after Pfizer Inc. (NYSE: PFE) indicated that its COVID-19 vaccine had prov...

The Medical Developments International Ltd (ASX: MVP) share price is on course to finish the week on a low note. In afternoon trade the healthcare company’s shares are down over 2% to $5.30. Why is the Medical Developments International sh...

The Medical Developments International Ltd (ASX: MVP) share price is pushing higher on the day of its annual general meeting. In afternoon trade the healthcare company’s shares are up 2.5% to $5.44. In case you missed the event, I thought...

Medical Developments International (ASX:MVP), the maker of the Penthrox (methoxyflurane) ‘green whistle’, has announced the appointment of Brent MacGregor as its new CEO.

The Medical Developments International Ltd (ASX: MVP) share price has surged 11.83% to $5.86 at the time of writing, after coming out of a trading halt this morning. Medical Developments had asked for a trading halt ahead of today’s announ...

The Medical Developments International Ltd (ASX: MVP) share price has fallen hard since COVID-19 put the world at a standstill. Between 19 February and 22 March, the Medical Developments share price took a sharp nosedive, falling from $11....

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Two out of...

The Medical Developments International Ltd (ASX: MVP) share price was out of form on Thursday. The healthcare company’s shares tumbled 9% lower to $6.04 following the release of its preliminary full year results. How did Medical Developmen...

Medical Developments International (ASX:MVP) has a tentative contract with the Mundipharma network in Europe to take back the distribution rights for its pain relief drug, Penthrox, in all 27 member states in the European Union. The stock j...

The Medical Developments International Ltd (ASX: MVP) share price returned from its trading halt and zoomed higher today. The healthcare company’s shares were up as much as 14% to $7.15 at one stage. At the time of writing the Medical Deve...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

As the economic outlook grows increasingly gloomy, many investors may be thinking of diversifying into defensive companies as a way of strengthening their portfolios. Generally, healthcare companies provide a good defence against a downtur...

Long-term shareholders of emerging ASX healthcare company Opthea Ltd (ASX: OPT) have endured a volatile 12 months. A little under a year ago, the Opthea share price was trading at a 52-week low of just $0.735. Then, in the space of a month...

Like many companies, junior ASX healthcare company Medical Developments International Limited (ASX: MVP) has had a volatile 2020. After soaring to an all-time high of $11.78 in February, the Medical Developments share price was savaged in...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Are you wanting to buy ASX shares today but are unsure where to look? Below are two ASX shares I would consider placing $5000 in for the next 3–5 years. Medical Developments International Ltd (ASX: MVP) Familiarity is a great place to st...

Medical Developments International (ASX:MVP) has announced the approval of pain reliever PENTHROX (methoxyflurane) in Thailand.

Well, are you? Here’s why I think it’s important to be prepared for the ASX to fall again. Where are we now? The All Ordinaries (ASX: XAO) fell almost 40% in late February to late March, with the S&P/ASX 200 Index (ASX: XJO) riding its...

Buying shares on the ASX doesn’t necessarily mean the business operates solely within Australian borders – after all, the world is a big place and Australia is only a relatively small market. So to accelerate growth, many companies look ac...

Investing in the ASX has no doubt felt a bit like a roller coaster over the past couple of months. The ALL ORDINARIES (ASX: XAO) fell almost 40% in March from its February highs, with the S&P/ASX 200 Index (ASX: XJO) not far behind, fa...

Is it time to buy Vanguard Australian Share ETF (ASX: VAS)? Vanguard Australian Share ETF is an exchange traded fund (ETF) focused on tracking the ASX 300 (ASX: XKO). What is Vanguard? I think Vanguard is great. Vanguard is a world leader...

Amid the insane volatility of financial markets, the CSL Limited (ASX: CSL) share price is actually trading more than 15% higher for the year. The company’s strong performance reflects its status as one of the finest shares listed on the A...

The Medical Developments International Ltd (ASX: MVP) share price is up 3.65% today, but Medical Developments shares have not been spared by the current market volatility, plunging more than 50% since mid-February.   Here’s why analysts ra...

We asked our Foolish writers to pick their favourite ASX stocks to buy in April.  Despite the coronavirus pandemic causing widespread volatility across global markets, we still see opportunities to buy amongst ASX shares.  So here is what...

The Medical Developments International Ltd (ASX: MVP) share price is pushing higher on Tuesday after releasing an update on the impact of the coronavirus on its business. At the time of writing the healthcare company’s shares are up 3.5% t...

The ASX healthcare sector continues to be one of the top performers on the ASX in terms of share price rises over the past 12 months, despite all the strong market correction. While most Australians are likely familiar with healthcare comp...

With coronavirus absolutely smashing global markets, investors and the public are turning to biotech companies for a solution. Currently, there is a global rush of medical trials to find a vaccine or medical product that could halt the cor...

Neuren Pharmaceuticals (ASX: NEU) is getting interesting results from a mouse trial of a treatment for Phelan-McDermid syndrome (PMS), a rare genetic illness which exhibits symptoms of conditions including autism and epilepsy. The study fou...

Neuroscience tech company Cogstate (ASX:CGS) produced some much needed good news today, saying it has executed $9.1m of clinical trials sales contracts since the start of 2020. The stock — up about 30 per cent on the news — says this revenu...

Medicall Developments International (ASX: MVP), the company responsible for a range of products including pain drug inhaler Penthrox, has announced the resignation of its CEO

The Australian share market may be storming higher on Thursday, but the Medical Developments International Ltd (ASX: MVP) share price hasn’t followed its lead. In morning trade the healthcare company’s shares are down 1% to $8.42. Why is t...

It is amazing how so many industries choose to hide behind their own jargon and acronyms. In IT, audio, and even the car industry – they all use terminology that makes them sound like experts in their own field but often fails to communica...

The Medical Developments International Ltd (ASX: MVP) share price is crashing lower on a day which has seen a sharp fall across most of the ASX’s major sectors.  At the time of writing, the S&P/ASX 200 Index (INDEXASX: XJO) is down 2.1...

Looking back over the past 12 months, the All Ordinaries (INDEXASX: XAO) has performed strongly, rising just over 15%. However, there are a number of shares that stood out and have managed to do even better. Below are three shares that hav...

The market may have dropped lower today, but that hasn’t stopped the Citadel Group Ltd (ASX: CGL) share price from charging higher. In afternoon trade the managed technology solutions provider’s shares are up 4% to $4.98. Why is the Citade...

Growing ASX-listed biotech company Paradigm Biopharmaceuticals Ltd (ASX: PAR) has performed strongly over the last year, with Paradigm shares skyrocketing more than 250% higher to $4.20 as at the time of writing. This means it has outperf...

The Australian market lost yesterday’s gains as the number of reported coronavirus cases nears 8000 and impacts Asian markets. Despite morning gains, the ASX 200 trailed off just over an hour into the session. The benchmark index relin...

The Opthea Ltd (ASX: OPT) share price has already surged over 20% higher in January to $3.60 as at the time of writing. Although the 52-week high of $4.15 the biotechnology company hit back in September still seems like a little way off ye...

Recently it was announced that CSL Limited (ASX: CSL) has been ranked as the third-most valuable biotech company in the world. The CSL share price cracked through the $300 per share barrier to start the year and is well poised to become th...

When looking for great long-term investments, it’s a good idea to start by looking at the big picture and asking yourself which sectors of the ASX you think will have a long-term advantage. I believe applying a macro-economic perspective t...

On Thursday the S&P/ASX 200 index broke through the 7,000 points mark for the first time in its history. But it wasn’t just the benchmark index that was hitting a new high. Several ASX shares raced to new highs of their own yesterday....

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

Outside of my portfolio holdings, I have a watchlist of around 25–30 shares I like to keep tabs on. I don’t follow them everyday, or even every week, but usually just absorb any major announcements released by the companies. Over time, thi...

The PolyNovo Ltd (ASX: PNV) share price has been a strong performer on Tuesday. The medical device company’s shares raced as much as 12% higher after returning from a trading halt this morning. They have since pulled back a touch, but are...

It’s easy to look back on ASX shares that you had wish you owned – hindsight is a marvellous thing. However, if we try to learn from it and understand what made certain companies perform better than others, maybe, just maybe, we won’t miss...

The Medical Developments International Ltd (ASX: MVP) share price has started 2020 on the right foot, up more than 5% at the time of writing and trading at all-time highs. The company’s share price outperformed in 2019, finishing the year...

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat...

Spies defecting, a foreign power secretly taking control of Australia via 5G, the stealthy infiltration of universities and CSIRO, a new arms race waged through cyber-warfare. This is not a John Le Carre novel, these are the headlines shapi...

Air pollution is a growing problem that in recent days has reached our own backyard. Because of the bushfires in surrounding areas, Sydney’s air has been ranked the ninth worst in the world. It’s not the first time in history it’s happened...